Seed Media Group

Search this blog

Profile

Karen%27s%20headshot.JPG Hi there. I am a science/ medical writer based in Atlanta GA. I am currently getting my Ph.D. in the field of cancer biochemistry at Emory University. The purpose of this blog is to write about current and interesting science news that may affect people's lives. I hope you enjoy my posts.

Science/Medical Writing
Jobs!


Brought to you by:

Hitt%20Medical%20Writing%20Logo.jpg

This Week's Featured Job:

Director, Scientific Reporting, San Antonio, Texas

Company: Genzyme (www.genzyme.com)
The Director of Scientific Reporting will provide leadership and supervision of top technical scientific writing staff focused on oncology and MS products.

Qualifications
Bachelor's Degree. (Preferred: Ph.D. in life science) Four years of management experience. Eight years of medical writing experience. Experience supporting regulatory submissions, both domestic and international.

For more details please contact Mary Reusser. Mary@chasegroup.com

Subscribe to The HittListTM for more science/medical writing jobs!

make%20request%20image.jpg.jpg Is there a topic you would like me to write about? Send me your requests here.

thinkingbloggerpf8.jpg

BANNER%20NOTICE.jpg Submit your entries for the Science To Life Banner Contest! Email your entries to sci2life@aol.com or Click here.

Recent Posts

Recent Comments

Archives

Blogroll

Other Information

.

« Interview with me | Main | Euthanasia Debate heats up in France »

Solving the drug price crisis

Category: HealthPharma
Posted on: March 18, 2008 10:49 PM, by Karen Ventii

pills%203-18.jpg
Two MIT pharmaceutical industry experts believe that the mounting U.S. drug price crisis can be contained and eventually reversed by separating drug discovery from drug marketing and by establishing a non-profit company to oversee funding for new medicines.

The experts are Stan Finkelstein, M.D., senior research scientist in MIT's Engineering Systems Division, and Peter Temin, Elisha Gray II Professor of Economics and they detail their proposal in their new book, "Reasonable Rx: Solving the Drug Price Crisis" (published by Financial Times Press).

Drawing on recent history, they propose dividing drug companies into drug discovery/development firms and drug marketing/distribution firms, just as electric utility firms were separated into generation and distribution companies in the 1990s.


Following the utility model, Finkelstein and Temin propose establishing an independent, public, non-profit Drug Development Corporation (DDC), which would act as an intermediary between the two new industry segments -- just as the electric grid acts as an intermediary between energy generators and distributors.

Derek Lowe, Ph.D., author of In the Pipeline, eloquently outlines his thoughts and concerns about this new proposal in his blog post. He says, "I have an instinctive distrust of plans that call for a board of dispassionate technocrats to step in and do things that the market is supposedly doing by itself." I enjoyed reading his take on the issue. Read more here.

Excerpts taken from this MIT press release

Comments

I'm not so sure deregulation would work for Pharma. I mean, the comparison to electricity rings hollow to me.

Why? Because I now pay almost double per kWh that I did pre-deregulation.

Posted by: Tony P | March 18, 2008 11:20 PM

It's not entirely clear to me that deregulation is the main cause of increased electricity cost.

Karen, thanks for blogging this. Very interesting idea.

Posted by: Zuska | March 20, 2008 2:51 PM

Very interesting. Thank you for the insight.


Find Free Pharmacy and Drug Coupons!

Posted by: Corinne | April 24, 2008 2:08 PM

Post a Comment

(Email is required for authentication purposes only. Comments are moderated for spam, your comment may not appear immediately. Thanks for waiting.)





Having problems commenting? (UPDATED)

Blogs in the Network

Advertisement

Top Five: Readers' Picks

Search All Blogs

Top Science Stories

powered by SEED - seedmagazine.com